What is Dermatophagoides farinae (D2) IgE?
Dermatophagoides farinae (D2)-specific IgE is an antibody produced by the immune system in response to allergens from the American house dust mite, Dermatophagoides farinae, and its detection in serum or skin testing identifies sensitization to this perennial indoor allergen that commonly causes allergic rhinitis, asthma, and atopic dermatitis.
Clinical Significance
Dermatophagoides farinae is one of the two most clinically important house dust mite species (along with D. pteronyssinus) that cause perennial allergic disease 1. When you measure D2-specific IgE, you are identifying patients who have developed allergic sensitization to this particular mite species.
Major Allergen Groups
The house dust mites D. farinae and D. pteronyssinus contain two major allergen groups that are immunologically cross-reactive 1:
- Der f 1 and Der p 1 (group 1 allergens)
- Der f 2 and Der p 2 (group 2 allergens)
More than 60% of mite-sensitive patients react to these two major allergen groups, with >70% sensitized to group 1 allergens and >80% to group 2 allergens 1, 2.
Diagnostic Testing
D2-specific IgE can be detected through:
- Serum testing (in vitro specific IgE measurement)
- Skin prick testing
- Nasal lavage fluid (for local allergic rhinitis) 3
The detection of specific IgE to D. farinae should correlate with clinical history of symptoms in dusty environments or perennial symptoms 1.
Clinical Patterns
Patients sensitized to house dust mites typically present with:
- Perennial symptoms exacerbated by dusty environments 1
- Allergic rhinitis with less prominent ocular symptoms compared to pollen allergies 4
- Asthma symptoms
- Atopic dermatitis
Important Clinical Caveat
Both research and clinical experience demonstrate that allergic rhinitis can exist in rare patients with negative skin tests and/or negative in vitro tests for specific IgE 4. These patients may have local nasal IgE production and positive nasal allergen provocation tests despite negative systemic testing—a condition known as local allergic rhinitis 3.
Cross-Reactivity Considerations
Due to the high degree of cross-allergenicity between the major allergens in D. pteronyssinus and D. farinae, only 50% of the projected amounts of each species needs to be included when preparing allergen immunotherapy extracts 1. This cross-reactivity means that sensitization to one species often implies reactivity to the other.
Treatment Implications
When D2-specific IgE is detected with corresponding clinical symptoms, immunotherapy for dust mites should be considered in conjunction with avoidance measures 1. Standardized dust mite immunotherapy is more effective than crude house dust allergen extracts 1.